-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Ketamine + Midazolam) in Sedation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Ketamine + Midazolam) in Sedation report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Ketamine + Midazolam) in Sedation Drug Details: A fixed dose combination...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OKYO-0101 in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OKYO-0101 in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OKYO-0101 in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: OKYO-0101 is...
-
Sector Analysis
Polycarbonate Industry Capacity and Capital Expenditure Forecasts with Details of Active and Planned Plants to 2027
Polycarbonate Industry Capacity & CapEx Overview The polycarbonate industry capacity was 7.59 million tonnes per annum (mtpa) in 2022 and is expected to increase at an AAGR of more than 5% during 2022-2027. Polycarbonate Industry Capacity and CapEx Outlook, 2022-2027 (mtpa) Buy the Full Report for More Insights on Polycarbonate Capacity and Capex Market Forecast Download a Free Report Sample The polycarbonate industry capacity and capital expenditure outlook provides updated information on all active, planned, and announced polycarbonate industry projects...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Midazolam Odt in Sedation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Midazolam Odt in Sedation report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Midazolam ODT in Sedation Drug Details:Midazolam (MELT-210) is under development for procedural sedation....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rhenium-188P2045 in Squamous Non-Small Cell Lung Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rhenium-188P2045 in Squamous Non-Small Cell Lung Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rhenium-188P2045 in Squamous Non-Small Cell Lung Carcinoma Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ligufalimab in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ligufalimab in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ligufalimab in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug...
-
Company Profile
Kurabo Industries Ltd – Company Profile
Kurabo Industries Ltd (Kurabo) manufactures textiles, chemical products, food, and advanced technology-related products. The company’s textile product portfolio comprises cotton, synthetic fiber, wool, linen, and other materials. Its chemical products portfolio comprises insulation film and hot-melt adhesive film among others. Kurabo’s engineering product portfolio comprises exhaust gas treatment equipment and heat treatment equipment among others. The company’s electronics product portfolio comprises infrastructure management systems, robot systems, infrared measuring devices, among others. It also offers services such as leasing of real...
Add to Basket -
Sector Analysis
Middle East and Africa (MEA) Health and Beauty Market Opportunities, Trends, Growth Analysis and Forecast to 2027
Middle East and Africa (MEA) Health and Beauty Market Report Overview The Middle East and Africa (MEA) health and beauty market size was $475 billion in 2022. The market is expected to record a CAGR of more than 4% during 2022-2027. Based on the relative performance of countries on multiple metrics, Saudi Arabia, Iran, the UAE, and Nigeria were shortlisted as high-potential countries. This choice was made primarily due to their large health & beauty industry sizes, projected high-value growth...